The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.
Identifieur interne : 003749 ( PubMed/Corpus ); précédent : 003748; suivant : 003750The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.
Auteurs : Andrea Gallamini ; Sally F. Barrington ; Alberto Biggi ; Stephane Chauvie ; Lale Kostakoglu ; Michele Gregianin ; Michel Meignan ; George N. Mikhaeel ; Annika Loft ; Jan M. Zaucha ; John F. Seymour ; Michael S. Hofman ; Luigi Rigacci ; Alessandro Pulsoni ; Morton Coleman ; Eldad J. Dann ; Livio Trentin ; Olivier Casasnovas ; Chiara Rusconi ; Pauline Brice ; Silvia Bolis ; Simonetta Viviani ; Flavia Salvi ; Stefano Luminari ; Martin HutchingsSource :
- Haematologica [ 1592-8721 ] ; 2014.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Fluorodeoxyglucose F18, Follow-Up Studies, Hodgkin Disease (diagnosis), Hodgkin Disease (mortality), Hodgkin Disease (therapy), Humans, Male, Middle Aged, Neoplasm Staging, Positron-Emission Tomography, Prognosis, Reproducibility of Results, Retrospective Studies, Sensitivity and Specificity, Treatment Outcome, Young Adult.
- MESH :
- chemical : Fluorodeoxyglucose F18.
- diagnosis : Hodgkin Disease.
- mortality : Hodgkin Disease.
- therapy : Hodgkin Disease.
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Positron-Emission Tomography, Prognosis, Reproducibility of Results, Retrospective Studies, Sensitivity and Specificity, Treatment Outcome, Young Adult.
Abstract
A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients with Hodgkin lymphoma; and (ii) the reproducibility of the Deauville five-point scale for the interpretation of interim positron emission tomography scan. Two hundred and sixty patients with newly diagnosed Hodgkin lymphoma were enrolled. Fifty-three patients with early unfavorable and 207 with advanced-stage disease were treated with doxorubicin, bleomycin, vinblastine and dacarbazine ± involved-field or consolidation radiotherapy. Positron emission tomography scan was performed at baseline and after two cycles of chemotherapy. Treatment was not changed according to the results of the interim scan. An international panel of six expert reviewers independently reported the scans using the Deauville five-point scale, blinded to treatment outcome. Forty-five scans were scored as positive (17.3%) and 215 (82.7%) as negative. After a median follow up of 37.0 (2-110) months, 252 patients are alive and eight have died. The 3-year progression-free survival rate was 83% for the whole study population, 28% for patients with interim positive scans and 95% for patients with interim negative scans (P<0.0001). The sensitivity, specificity, and negative and positive predictive values of interim positron emission tomography scans for predicting treatment outcome were 0.73, 0.94, 0.94 and 0.73, respectively. Binary concordance amongst reviewers was good (Cohen's kappa 0.69-0.84). In conclusion, the prognostic role and validity of the Deauville five-point scale for interpretation of interim positron emission tomography scans have been confirmed by the present study.
DOI: 10.3324/haematol.2013.103218
PubMed: 24658820
Links to Exploration step
pubmed:24658820Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.</title><author><name sortKey="Gallamini, Andrea" sort="Gallamini, Andrea" uniqKey="Gallamini A" first="Andrea" last="Gallamini">Andrea Gallamini</name><affiliation><nlm:affiliation>Research and Medical Innovation Department, Centre Antoine Lacassagne, Nice, France gallamini.a@ospedale.cuneo.it.</nlm:affiliation></affiliation></author><author><name sortKey="Barrington, Sally F" sort="Barrington, Sally F" uniqKey="Barrington S" first="Sally F" last="Barrington">Sally F. Barrington</name><affiliation><nlm:affiliation>Division of Imaging, King's College London, PET Centre, Guy's & St. Thomas' Hospital, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Biggi, Alberto" sort="Biggi, Alberto" uniqKey="Biggi A" first="Alberto" last="Biggi">Alberto Biggi</name><affiliation><nlm:affiliation>Nuclear Medicine Department, PET Center, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Chauvie, Stephane" sort="Chauvie, Stephane" uniqKey="Chauvie S" first="Stephane" last="Chauvie">Stephane Chauvie</name><affiliation><nlm:affiliation>Medical Physics Unit, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Kostakoglu, Lale" sort="Kostakoglu, Lale" uniqKey="Kostakoglu L" first="Lale" last="Kostakoglu">Lale Kostakoglu</name><affiliation><nlm:affiliation>Department of Radiology, Division of Nuclear Medicine, Mount Sinai Medical Center, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Gregianin, Michele" sort="Gregianin, Michele" uniqKey="Gregianin M" first="Michele" last="Gregianin">Michele Gregianin</name><affiliation><nlm:affiliation>Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Meignan, Michel" sort="Meignan, Michel" uniqKey="Meignan M" first="Michel" last="Meignan">Michel Meignan</name><affiliation><nlm:affiliation>Nuclear Medicine Department, Centre Universitaire Hospitalier Henri Mondor, Creteril, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mikhaeel, George N" sort="Mikhaeel, George N" uniqKey="Mikhaeel G" first="George N" last="Mikhaeel">George N. Mikhaeel</name><affiliation><nlm:affiliation>Clinical Oncology Department. Guy's & St. Thomas' Hospital, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Loft, Annika" sort="Loft, Annika" uniqKey="Loft A" first="Annika" last="Loft">Annika Loft</name><affiliation><nlm:affiliation>PET & Cyclotron Unit, Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen University Hospital, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Zaucha, Jan M" sort="Zaucha, Jan M" uniqKey="Zaucha J" first="Jan M" last="Zaucha">Jan M. Zaucha</name><affiliation><nlm:affiliation>Department of Oncology, Gdynia Oncology Centre & Department of Propedeutic Oncology, University of Gdansk, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Seymour, John F" sort="Seymour, John F" uniqKey="Seymour J" first="John F" last="Seymour">John F. Seymour</name><affiliation><nlm:affiliation>Haematology Department, Peter MacCallum Cancer Centre, Melbourne, and University of Melbourne, Parkville Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hofman, Michael S" sort="Hofman, Michael S" uniqKey="Hofman M" first="Michael S" last="Hofman">Michael S. Hofman</name><affiliation><nlm:affiliation>Center for Cancer Imaging Peter Mac Callum Cancer Center, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Rigacci, Luigi" sort="Rigacci, Luigi" uniqKey="Rigacci L" first="Luigi" last="Rigacci">Luigi Rigacci</name><affiliation><nlm:affiliation>Hematology Department, University of Florence, Careggi Hospital, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Pulsoni, Alessandro" sort="Pulsoni, Alessandro" uniqKey="Pulsoni A" first="Alessandro" last="Pulsoni">Alessandro Pulsoni</name><affiliation><nlm:affiliation>Cellular Biotechnology and Hematology Department, Sapienza University, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Coleman, Morton" sort="Coleman, Morton" uniqKey="Coleman M" first="Morton" last="Coleman">Morton Coleman</name><affiliation><nlm:affiliation>Hematology-Oncology Division, Center for Lymphoma & Myeloma, Weill Cornell Medical Center, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dann, Eldad J" sort="Dann, Eldad J" uniqKey="Dann E" first="Eldad J" last="Dann">Eldad J. Dann</name><affiliation><nlm:affiliation>Department of Hematology & Bone Marrow Transplantation; Rambam Medical Center, Haifa, Israel.</nlm:affiliation></affiliation></author><author><name sortKey="Trentin, Livio" sort="Trentin, Livio" uniqKey="Trentin L" first="Livio" last="Trentin">Livio Trentin</name><affiliation><nlm:affiliation>Hematology Department, University of Padua, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Casasnovas, Olivier" sort="Casasnovas, Olivier" uniqKey="Casasnovas O" first="Olivier" last="Casasnovas">Olivier Casasnovas</name><affiliation><nlm:affiliation>Hematology Department, Hopital Le Bocage, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rusconi, Chiara" sort="Rusconi, Chiara" uniqKey="Rusconi C" first="Chiara" last="Rusconi">Chiara Rusconi</name><affiliation><nlm:affiliation>Hematology Department - Niguarda Ca' Granda Hospital, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Brice, Pauline" sort="Brice, Pauline" uniqKey="Brice P" first="Pauline" last="Brice">Pauline Brice</name><affiliation><nlm:affiliation>Hematology Department Centre Hospitalier Universitaire St. Louis, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bolis, Silvia" sort="Bolis, Silvia" uniqKey="Bolis S" first="Silvia" last="Bolis">Silvia Bolis</name><affiliation><nlm:affiliation>Hematology Department, S. Gerardo University Hospital, Monza, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Viviani, Simonetta" sort="Viviani, Simonetta" uniqKey="Viviani S" first="Simonetta" last="Viviani">Simonetta Viviani</name><affiliation><nlm:affiliation>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Salvi, Flavia" sort="Salvi, Flavia" uniqKey="Salvi F" first="Flavia" last="Salvi">Flavia Salvi</name><affiliation><nlm:affiliation>Department of Hematology, SS Antonio e Biagio Hospital, Alessandria, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Luminari, Stefano" sort="Luminari, Stefano" uniqKey="Luminari S" first="Stefano" last="Luminari">Stefano Luminari</name><affiliation><nlm:affiliation>Onco-Hematology Department, Modena University, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Hutchings, Martin" sort="Hutchings, Martin" uniqKey="Hutchings M" first="Martin" last="Hutchings">Martin Hutchings</name><affiliation><nlm:affiliation>Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24658820</idno><idno type="pmid">24658820</idno><idno type="doi">10.3324/haematol.2013.103218</idno><idno type="wicri:Area/PubMed/Corpus">003749</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003749</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.</title><author><name sortKey="Gallamini, Andrea" sort="Gallamini, Andrea" uniqKey="Gallamini A" first="Andrea" last="Gallamini">Andrea Gallamini</name><affiliation><nlm:affiliation>Research and Medical Innovation Department, Centre Antoine Lacassagne, Nice, France gallamini.a@ospedale.cuneo.it.</nlm:affiliation></affiliation></author><author><name sortKey="Barrington, Sally F" sort="Barrington, Sally F" uniqKey="Barrington S" first="Sally F" last="Barrington">Sally F. Barrington</name><affiliation><nlm:affiliation>Division of Imaging, King's College London, PET Centre, Guy's & St. Thomas' Hospital, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Biggi, Alberto" sort="Biggi, Alberto" uniqKey="Biggi A" first="Alberto" last="Biggi">Alberto Biggi</name><affiliation><nlm:affiliation>Nuclear Medicine Department, PET Center, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Chauvie, Stephane" sort="Chauvie, Stephane" uniqKey="Chauvie S" first="Stephane" last="Chauvie">Stephane Chauvie</name><affiliation><nlm:affiliation>Medical Physics Unit, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Kostakoglu, Lale" sort="Kostakoglu, Lale" uniqKey="Kostakoglu L" first="Lale" last="Kostakoglu">Lale Kostakoglu</name><affiliation><nlm:affiliation>Department of Radiology, Division of Nuclear Medicine, Mount Sinai Medical Center, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Gregianin, Michele" sort="Gregianin, Michele" uniqKey="Gregianin M" first="Michele" last="Gregianin">Michele Gregianin</name><affiliation><nlm:affiliation>Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Meignan, Michel" sort="Meignan, Michel" uniqKey="Meignan M" first="Michel" last="Meignan">Michel Meignan</name><affiliation><nlm:affiliation>Nuclear Medicine Department, Centre Universitaire Hospitalier Henri Mondor, Creteril, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mikhaeel, George N" sort="Mikhaeel, George N" uniqKey="Mikhaeel G" first="George N" last="Mikhaeel">George N. Mikhaeel</name><affiliation><nlm:affiliation>Clinical Oncology Department. Guy's & St. Thomas' Hospital, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Loft, Annika" sort="Loft, Annika" uniqKey="Loft A" first="Annika" last="Loft">Annika Loft</name><affiliation><nlm:affiliation>PET & Cyclotron Unit, Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen University Hospital, Denmark.</nlm:affiliation></affiliation></author><author><name sortKey="Zaucha, Jan M" sort="Zaucha, Jan M" uniqKey="Zaucha J" first="Jan M" last="Zaucha">Jan M. Zaucha</name><affiliation><nlm:affiliation>Department of Oncology, Gdynia Oncology Centre & Department of Propedeutic Oncology, University of Gdansk, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Seymour, John F" sort="Seymour, John F" uniqKey="Seymour J" first="John F" last="Seymour">John F. Seymour</name><affiliation><nlm:affiliation>Haematology Department, Peter MacCallum Cancer Centre, Melbourne, and University of Melbourne, Parkville Victoria, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Hofman, Michael S" sort="Hofman, Michael S" uniqKey="Hofman M" first="Michael S" last="Hofman">Michael S. Hofman</name><affiliation><nlm:affiliation>Center for Cancer Imaging Peter Mac Callum Cancer Center, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Rigacci, Luigi" sort="Rigacci, Luigi" uniqKey="Rigacci L" first="Luigi" last="Rigacci">Luigi Rigacci</name><affiliation><nlm:affiliation>Hematology Department, University of Florence, Careggi Hospital, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Pulsoni, Alessandro" sort="Pulsoni, Alessandro" uniqKey="Pulsoni A" first="Alessandro" last="Pulsoni">Alessandro Pulsoni</name><affiliation><nlm:affiliation>Cellular Biotechnology and Hematology Department, Sapienza University, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Coleman, Morton" sort="Coleman, Morton" uniqKey="Coleman M" first="Morton" last="Coleman">Morton Coleman</name><affiliation><nlm:affiliation>Hematology-Oncology Division, Center for Lymphoma & Myeloma, Weill Cornell Medical Center, New York, NY, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Dann, Eldad J" sort="Dann, Eldad J" uniqKey="Dann E" first="Eldad J" last="Dann">Eldad J. Dann</name><affiliation><nlm:affiliation>Department of Hematology & Bone Marrow Transplantation; Rambam Medical Center, Haifa, Israel.</nlm:affiliation></affiliation></author><author><name sortKey="Trentin, Livio" sort="Trentin, Livio" uniqKey="Trentin L" first="Livio" last="Trentin">Livio Trentin</name><affiliation><nlm:affiliation>Hematology Department, University of Padua, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Casasnovas, Olivier" sort="Casasnovas, Olivier" uniqKey="Casasnovas O" first="Olivier" last="Casasnovas">Olivier Casasnovas</name><affiliation><nlm:affiliation>Hematology Department, Hopital Le Bocage, Dijon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rusconi, Chiara" sort="Rusconi, Chiara" uniqKey="Rusconi C" first="Chiara" last="Rusconi">Chiara Rusconi</name><affiliation><nlm:affiliation>Hematology Department - Niguarda Ca' Granda Hospital, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Brice, Pauline" sort="Brice, Pauline" uniqKey="Brice P" first="Pauline" last="Brice">Pauline Brice</name><affiliation><nlm:affiliation>Hematology Department Centre Hospitalier Universitaire St. Louis, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Bolis, Silvia" sort="Bolis, Silvia" uniqKey="Bolis S" first="Silvia" last="Bolis">Silvia Bolis</name><affiliation><nlm:affiliation>Hematology Department, S. Gerardo University Hospital, Monza, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Viviani, Simonetta" sort="Viviani, Simonetta" uniqKey="Viviani S" first="Simonetta" last="Viviani">Simonetta Viviani</name><affiliation><nlm:affiliation>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Salvi, Flavia" sort="Salvi, Flavia" uniqKey="Salvi F" first="Flavia" last="Salvi">Flavia Salvi</name><affiliation><nlm:affiliation>Department of Hematology, SS Antonio e Biagio Hospital, Alessandria, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Luminari, Stefano" sort="Luminari, Stefano" uniqKey="Luminari S" first="Stefano" last="Luminari">Stefano Luminari</name><affiliation><nlm:affiliation>Onco-Hematology Department, Modena University, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Hutchings, Martin" sort="Hutchings, Martin" uniqKey="Hutchings M" first="Martin" last="Hutchings">Martin Hutchings</name><affiliation><nlm:affiliation>Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Haematologica</title><idno type="eISSN">1592-8721</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Fluorodeoxyglucose F18</term><term>Follow-Up Studies</term><term>Hodgkin Disease (diagnosis)</term><term>Hodgkin Disease (mortality)</term><term>Hodgkin Disease (therapy)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Positron-Emission Tomography</term><term>Prognosis</term><term>Reproducibility of Results</term><term>Retrospective Studies</term><term>Sensitivity and Specificity</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Fluorodeoxyglucose F18</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hodgkin Disease</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Hodgkin Disease</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Hodgkin Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Staging</term><term>Positron-Emission Tomography</term><term>Prognosis</term><term>Reproducibility of Results</term><term>Retrospective Studies</term><term>Sensitivity and Specificity</term><term>Treatment Outcome</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients with Hodgkin lymphoma; and (ii) the reproducibility of the Deauville five-point scale for the interpretation of interim positron emission tomography scan. Two hundred and sixty patients with newly diagnosed Hodgkin lymphoma were enrolled. Fifty-three patients with early unfavorable and 207 with advanced-stage disease were treated with doxorubicin, bleomycin, vinblastine and dacarbazine ± involved-field or consolidation radiotherapy. Positron emission tomography scan was performed at baseline and after two cycles of chemotherapy. Treatment was not changed according to the results of the interim scan. An international panel of six expert reviewers independently reported the scans using the Deauville five-point scale, blinded to treatment outcome. Forty-five scans were scored as positive (17.3%) and 215 (82.7%) as negative. After a median follow up of 37.0 (2-110) months, 252 patients are alive and eight have died. The 3-year progression-free survival rate was 83% for the whole study population, 28% for patients with interim positive scans and 95% for patients with interim negative scans (P<0.0001). The sensitivity, specificity, and negative and positive predictive values of interim positron emission tomography scans for predicting treatment outcome were 0.73, 0.94, 0.94 and 0.73, respectively. Binary concordance amongst reviewers was good (Cohen's kappa 0.69-0.84). In conclusion, the prognostic role and validity of the Deauville five-point scale for interpretation of interim positron emission tomography scans have been confirmed by the present study.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24658820</PMID><DateCreated><Year>2014</Year><Month>06</Month><Day>02</Day></DateCreated><DateCompleted><Year>2015</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1592-8721</ISSN><JournalIssue CitedMedium="Internet"><Volume>99</Volume><Issue>6</Issue><PubDate><Year>2014</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Haematologica</Title><ISOAbbreviation>Haematologica</ISOAbbreviation></Journal><ArticleTitle>The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.</ArticleTitle><Pagination><MedlinePgn>1107-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3324/haematol.2013.103218</ELocationID><Abstract><AbstractText>A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients with Hodgkin lymphoma; and (ii) the reproducibility of the Deauville five-point scale for the interpretation of interim positron emission tomography scan. Two hundred and sixty patients with newly diagnosed Hodgkin lymphoma were enrolled. Fifty-three patients with early unfavorable and 207 with advanced-stage disease were treated with doxorubicin, bleomycin, vinblastine and dacarbazine ± involved-field or consolidation radiotherapy. Positron emission tomography scan was performed at baseline and after two cycles of chemotherapy. Treatment was not changed according to the results of the interim scan. An international panel of six expert reviewers independently reported the scans using the Deauville five-point scale, blinded to treatment outcome. Forty-five scans were scored as positive (17.3%) and 215 (82.7%) as negative. After a median follow up of 37.0 (2-110) months, 252 patients are alive and eight have died. The 3-year progression-free survival rate was 83% for the whole study population, 28% for patients with interim positive scans and 95% for patients with interim negative scans (P<0.0001). The sensitivity, specificity, and negative and positive predictive values of interim positron emission tomography scans for predicting treatment outcome were 0.73, 0.94, 0.94 and 0.73, respectively. Binary concordance amongst reviewers was good (Cohen's kappa 0.69-0.84). In conclusion, the prognostic role and validity of the Deauville five-point scale for interpretation of interim positron emission tomography scans have been confirmed by the present study.</AbstractText><CopyrightInformation>Copyright© Ferrata Storti Foundation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gallamini</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research and Medical Innovation Department, Centre Antoine Lacassagne, Nice, France gallamini.a@ospedale.cuneo.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barrington</LastName><ForeName>Sally F</ForeName><Initials>SF</Initials><AffiliationInfo><Affiliation>Division of Imaging, King's College London, PET Centre, Guy's & St. Thomas' Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biggi</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Department, PET Center, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chauvie</LastName><ForeName>Stephane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Physics Unit, Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostakoglu</LastName><ForeName>Lale</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Radiology, Division of Nuclear Medicine, Mount Sinai Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gregianin</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meignan</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nuclear Medicine Department, Centre Universitaire Hospitalier Henri Mondor, Creteril, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikhaeel</LastName><ForeName>George N</ForeName><Initials>GN</Initials><AffiliationInfo><Affiliation>Clinical Oncology Department. Guy's & St. Thomas' Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loft</LastName><ForeName>Annika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>PET & Cyclotron Unit, Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen University Hospital, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaucha</LastName><ForeName>Jan M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Oncology, Gdynia Oncology Centre & Department of Propedeutic Oncology, University of Gdansk, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seymour</LastName><ForeName>John F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Haematology Department, Peter MacCallum Cancer Centre, Melbourne, and University of Melbourne, Parkville Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hofman</LastName><ForeName>Michael S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Center for Cancer Imaging Peter Mac Callum Cancer Center, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigacci</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hematology Department, University of Florence, Careggi Hospital, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pulsoni</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cellular Biotechnology and Hematology Department, Sapienza University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coleman</LastName><ForeName>Morton</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology-Oncology Division, Center for Lymphoma & Myeloma, Weill Cornell Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dann</LastName><ForeName>Eldad J</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Hematology & Bone Marrow Transplantation; Rambam Medical Center, Haifa, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trentin</LastName><ForeName>Livio</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hematology Department, University of Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casasnovas</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Hematology Department, Hopital Le Bocage, Dijon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rusconi</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Hematology Department - Niguarda Ca' Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brice</LastName><ForeName>Pauline</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hematology Department Centre Hospitalier Universitaire St. Louis, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolis</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hematology Department, S. Gerardo University Hospital, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viviani</LastName><ForeName>Simonetta</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvi</LastName><ForeName>Flavia</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Hematology, SS Antonio e Biagio Hospital, Alessandria, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luminari</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Onco-Hematology Department, Modena University, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hutchings</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Haematologica</MedlineTA><NlmUniqueID>0417435</NlmUniqueID><ISSNLinking>0390-6078</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1989 Nov;7(11):1630-6</RefSource><PMID Version="1">2809679</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Chemother Rep. 1966 Mar;50(3):163-70</RefSource><PMID Version="1">5910392</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 1998 Nov 19;339(21):1506-14</RefSource><PMID Version="1">9819449</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2005 Jul;16(7):1160-8</RefSource><PMID Version="1">15939713</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2005 Aug 15;106(4):1376-81</RefSource><PMID Version="1">15860666</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2006 Jan 1;107(1):52-9</RefSource><PMID Version="1">16150944</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2006 Apr;91(4):475-81</RefSource><PMID Version="1">16585014</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2006 Apr;91(4):522-9</RefSource><PMID Version="1">16585017</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2006 Jun;47(6):1059-66</RefSource><PMID Version="1">16741317</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2006 Aug;17(8):1296-300</RefSource><PMID Version="1">16766583</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer. 2006 Dec 1;107(11):2678-87</RefSource><PMID Version="1">17063502</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 Aug 20;25(24):3746-52</RefSource><PMID Version="1">17646666</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2007 Nov 15;110(10):3507-16</RefSource><PMID Version="1">17709603</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Apr 10;27(11):1906-14</RefSource><PMID Version="1">19273713</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Jun 1;27(16):2739-41</RefSource><PMID Version="1">19398565</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2009 Nov;50(11):1761-4</RefSource><PMID Version="1">19883305</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2009 Aug;50(8):1257-60</RefSource><PMID Version="1">19544140</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):181-200</RefSource><PMID Version="1">19915839</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2010 Sep;51(9):1337-43</RefSource><PMID Version="1">20720036</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1824-33</RefSource><PMID Version="1">20505930</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2010 Dec;51(12):1857-62</RefSource><PMID Version="1">21078789</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2010 Dec;51(12):2171-80</RefSource><PMID Version="1">21077737</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Nucl Med Mol Imaging. 2012 Jan;39(1):4-12</RefSource><PMID Version="1">21894546</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Nucl Med. 2013 May;54(5):683-90</RefSource><PMID Version="1">23516309</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1999 Apr;17(4):1244</RefSource><PMID Version="1">10561185</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Comput Methods Programs Biomed. 2000 Aug;63(1):43-6</RefSource><PMID Version="1">10927153</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1996 May;14(5):1421-30</RefSource><PMID Version="1">8622055</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006689" MajorTopicYN="N">Hodgkin Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4040916</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24658820</ArticleId><ArticleId IdType="pii">haematol.2013.103218</ArticleId><ArticleId IdType="doi">10.3324/haematol.2013.103218</ArticleId><ArticleId IdType="pmc">PMC4040916</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003749 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003749 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24658820
|texte= The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24658820" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |